Return to Faculty List

Faculty

Azita H. Talasaz

Associate Professor, Pharmacy Practice Full-time

Pharm.D., Tehran University of Medical Sciences, Tehran, IranPhD/ Residency, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Description

Dr. Talasaz is an Associate Professor of Pharmacy Practice at Long Island University, and currently practices as Clinical Pharmacist in Critical Care Unit and Cardiothoracic Intensive Care Unit at NewYork Presbyterian Columbia University Medical Center. 

Before moving to the US, she was a Tenured Professor in the Department of Clinical Pharmacy at Tehran University of Medical Sciences and a Cardiology Pharmacist in Tehran Heart Center – the referral center for cardiovascular disease in Iran. She has completed her Experimental Cardiovascular Pharmacotherapy Research Fellowship at Virginia Commonwealth University (VCU) then transitioned into Research Faculty at VCU in Richmond, VA. She is an active researcher in cardiovascular pharmacotherapy, and has published over 110 peer-reviewed manuscripts, primarily focusing on the antithrombotic agents and management of patients with acute cardiovascular diseases. Dr. Talasaz is a Cardiology Pharmacy Specialty Council Member (Board of Pharmacy Specialists) and Council on Clinical Cardiology Clinical Pharmacology Committee Member (American Heart Association). She is a fellow of the American College of Clinical Pharmacy (ACCP), and the American College of Cardiology (ACC).

Specialties

Cardiovascular pharmacotherapy, antithrombotic agents, heart failure

Publications

  • Bond R, Gibson CM, Talasaz AH, Van Tassell BW. Analysis of Gender and Race in Pharmacy Faculty and Administrators. Am J Pharm Educ. 2023 Sep 9:100585. doi: 10.1016/j.ajpe.2023.100585.
  • Talasaz AH, Donohoe KL, Van Tassell B; VCU Curriculum Investigators. Curriculum mapping of accredited pharmacy programs in the United States. Curr Pharm Teach Learn. 2023 Jun 28:S1877-1297(23)00154-5. doi: 10.1016/j.cptl.2023.06.017.
  • Talasaz A, Sculthorpe R, Pak M, Lipinski M, Roberts C, Markley R, Trankle C, Canada JM, Wohlford GF, Golino M, Dixon DL, Van Tassell B, Abbate A. Comparison of safety and biological efficacy of anakinra (Kineret ®) dispensed in polycarbonate plastic versusborosilicate glass syringes: a patient-level analysis of VCUART2 and VCUART3 clinical trials. J Pharmacol Exp Ther. 2023 Mar 3:JPET-AR-2022-001404.
  • Talasaz AH, Sadeghipour P, et al on behalf of INSPIRATION Investigators. Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial. Thromb Haemost. 2023 Mar 21. doi: 10.1055/a-2059-4844.
  • Talasaz AH, Sadeghipour P, Mehdizadeh K, Khoshnam Rad N, Bikdeli B, Lip GYH, Harenberg J. Knowledge Gaps for Prophylactic Use of Antithrombotic Agents in Patients with COVID-19: Insights into New SARS-CoV-2 Variants, Vaccination Status, and Emerging Oral Antivirals. Thromb Haemost. 2023 Feb;123(2):186-191.
  • Kakavand H, Aghakouchakzadeh M, Shahi A, Virani SS, Dixon DL, Van Tassell BW, Talasaz AH. A Stepwise Approach to Prescribing Novel Lipid-Lowering Medications. Journal of Clinical Lipidology. 2022 Oct 19.
  • Ortega-Paz L, Talasaz AH, Sadeghipour P, Potpara TS, Aronow HD, Jara-Palomares L, Sholzberg M, Angiolillo DJ, Lip GYH, Bikdeli B. COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment. Semin Thromb Hemost. 2022 Oct 12. doi: 10.1055/s-0042-1757634.
  • INSPIRATION Investigators. Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes. Eur J Intern Med. 2022 Jun 20;103:76–83. doi: 10.1016/j.ejim.2022.06.014.
  • Van Tassell B, Mihalick V, Thomas G, Marawan A, Talasaz AH, Lu J, Kang L, Ladd A, Damonte JI, Dixon DL, Markley R, Turlington J, Federmann E, Del Buono MG, Biondi-Zoccai G, Canada JM, Arena R, Abbate A. Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study. J Transl Med. 2022 Jun 15;20(1):270. doi: 10.1186/s12967-022-03466-9.
  • Dixon DL, Patel J, Spence R, Talasaz AH, Abbate A, Wiggins BS. Select drug-drug interactions with colchicine and cardiovascular medications: A review. Am Heart J. 2022 Jun 14;252:42-50. doi: 10.1016/j.ahj.2022.06.002.
  • Talasaz AH, Hosseini, SH, Alidoosti, M, Tajdini, M, Van Tassell, B, Etesamifard, N, Kakavand, H, Jalali, A, Aghakouchakzadeh, M, Gheymati, A, Sadeghian, M, Jenab, Y. Pre-Procedural Colchicine in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: a Randomized Controlled Trial (PodCAST-PCI), Journal of Cardiovascular Pharmacology: June 22, 2022
  • Bikdeli B, Zahedi Tajrishi F, Sadeghipour P, Talasaz AH, Fanikos J, Lippi G, Siegal DM, Eikelboom JW, Monreal M, Jimenez D, Connors JM, Ageno W, Barnes GD, Piazza G, Angiolillo DJ, Parikh SA, Kirtane AJ, Lopes RD, Bhatt DL, Weitz JI, Mehran R, Krumholz HM, Goldhaber SZ, Lip GYH. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review. JAMA Cardiol. 2022 Jun 1. doi: 10.1001/jamacardio.2022.1292.
  • Mihalick V, Wohlford G, Talasaz AH, Ho AJ, Kim F, Canada JM, Carbone S, Kadariya D, Billingsley H, Trankle C, Del Buono MG, Moroni F, Arena R, Abbate A, Van Tassell B. Patient Perceptions of Exertion and Dyspnea With Interleukin-1 Blockade in Patients With Recently Decompensated Systolic Heart Failure. Am J Cardiol. 2022 Jul 1;174:61-67. doi: 10.1016/j.amjcard.2022.03.026.
  • Talasaz AH, Salehiomran A, Heidary Z, Gholami K, Aryannejad H, Jalali A, Daei M. The effects of vitamin D supplementation on postoperative atrial fibrillation after coronary artery bypass grafting in patients with vitamin D deficiency. J Card Surg. 2022 Jul;37(7):2219-2224. doi: 10.1111/jocs.16550.
  • INSPIRATION Investigators, Sadeghipour P, Talasaz AH, et al. Atorvastatin versus Placebo in Patients with COVID-19 Admitted to the Intensive Caro Unit: The INSPIRATION-S Randomised Controlled Trial. BMJ; 2022 Jan 7;376:e068407. doi: 10.1136/bmj-2021-068407.
  • Talasaz AH, Jane Ho AC, Bhatty F, Koenig RA, Dixon DL, Baker WL, Van Tassell BW. Meta-Analysis of Clinical Outcomes of PCSK9 Modulators in Patients with Established ASCVD. Pharmacotherapy. 2021 Oct 17. doi: 10.1002/phar.2635. Epub ahead of print. PMID: 34657313.
  • Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H, Gupta A, Madhavan MV, Van Tassell BW, Jimenez D, Monreal M, Vaduganathan M, Fanikos J, Dixon DL, Piazza G, Parikh SA, Bhatt DL, Lip GY, Stone GW, Krumholz HM, Libby P, Goldhaber SZ, Bikdeli B. Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials. JACC. 2021 Oct 19:2021.
  • Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Kakavand H, Ariannejad H, Connors JM, Hunt BJ, Berger JS, Van Tassell BW, Middeldorp S, Piazza G, Weitz JI, Cushman M, Lip GYH, Goldhaber SZ, Bikdeli B. Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. J Thromb Haemost. 2021 Sep 19. doi: 10.1111/jth.15533. Epub ahead of print. PMID: 34538017.
  • Talasaz AH, Bikdeli B, Rashidi F, INSPIRATION Investigators. Intermediate vs Standard-dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to ICU: Ninety-day Results from the INSPIRATION Trial. Thromb Haemost. 2021 Apr 17. doi: 10.1055/a-1485-2372.
  • Sadeghipour P, Talasaz AH, Rashidi F, INSPIRATION Investigators. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA, Published online March 18, 2021.
  • Talasaz, A.H., Sadeghipour, P., Kakavand, H., Aghakouchakzadeh, M., Van Tassell, B.W., Kordzadeh-Kermani, E., Gheymati, A., Ariannrjad, H., Hosseini, S.H., Jamalkhani, S. and Sholzberg, M., 2021. Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials. Journal of American College of Cardiology, Mar 16, 2021. Epublished DOI: 10.1016/j.jacc.2021.02.035
  • Kakavand H, Aghakouchakzadeh M, Coons J, Talasaz AH*. Pharmacologic Prevention of Myocardial Ischemia-Reperfusion Injury in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Journal of Cardiovascular Pharmacology. 2021, Published ahead of print.
  • Bikdeli B, Talasaz AH, Rashidi F, Sharif-Kashani B, Farrokhpour M, Bakhshandeh H, et al. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. Thromb Res 2020 Dec;196:382-394.
  • Talasaz AH, Kakavand H, Van Tassell BW, Sadeghipour P, Aghakouchakzadeh M, Dunn SP, Geraieli B. Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective. Cardiovasc Drugs Ther. 2020 Jul 15. doi: 10.1007/s10557-020-07037-2. (2020).
  • Dixon DL, Van Tassell BW, Vecchié A , Bonaventura A , Talasaz AH , Kakavand H, et al. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). J Cardiovasc Pharmacol. 2020 May;75(5):359-367.
  • Sadeghipour P, Talasaz AH, Eslami V, et al. Management of ST-segment-elevation myocardial infarction during the coronavirus disease 2019 (COVID -19) outbreak: Iranian“247” National Committee's position paper on primary percutaneous coronary intervention. Catheterization and Cardiovascular Interventions (2020). https://doi.org/10.1002/ccd.28889.
  • Ghaeli P, Solduzian M, Vejdani S, Talasaz AH*. Comparison of the Effects of Melatonin and Oxazepam on Anxiety Levels and Sleep Quality in Patients With ST-Segment-Elevation Myocardial Infarction Following Primary Percutaneous Coronary Intervention: A Randomized Clinical Trial. Ann Pharmacother. 2018 Oct;52(10):949-955. doi: 10.1177/1060028018776608. Epub 2018 May 11.
  • Nozari Y, Eshraghi A, Talasaz AH, Bahremand M, Salamzadeh J, Salarifar M, Pourhosseini H, Jalali A, Mortazavi SH. Protection from Reperfusion Injury with Intracoronary N-Acetylcysteine in Patients with STEMI Undergoing Primary Percutaneous Coronary Intervention in a Cardiac Tertiary Center. Am J Cardiovasc Drugs. 2018 Jun;18(3):213-221. doi: 10.1007/s40256-017-0258-8.
  • Ghaffary S, Ghaeli P, Talasaz AH*, Karimi A, Noroozian M, Salehiomran A, Jalali A. Effect of memantine on post-operative cognitive dysfunction after cardiac surgeries: a randomized clinical trial. Daru. 2017 Nov 21;25(1):24. doi: 10.1186/s40199-017-0190-0.
  • Boroumand M, Pourgholi L, Goodarzynejad H, Ziaee S, Talasaz AH, Sotoudeh-Anvari M, Mandegary A. NQO1 C609T Polymorphism is Associated with Coronary Artery Disease in a Gender-Dependent Manner. Cardiovasc Toxicol. 2017 Jan;17(1):35-41. doi: 10.1007/s12012-015-9353-8.
  • Ghelich Khan Z, Talasaz AH*, Pourhosseini H, Hosseini K, Alemzadeh Ansari MJ, Jalali A. Potential Role of Allopurinol in Preventing Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention: A Randomized Placebo-Controlled Trial. Clin Drug Investig. 2017 Sep;37(9):853-860. doi: 10.1007/s40261-017-0542-z.
  • Izadi Amoli A, Bozorgi A, Talasaz AH, Salehi Omran A, Mortazavi SH, Jalali A, Nasirpour S, Jenab Y. Efficacy of colchicine versus placebo for the treatment of pericardial effusion after open-heart surgery: A randomized, placebo-controlled trial. Am Heart J. 2015 Dec;170(6):1195-201. doi: 10.1016/j.ahj.2015.09.020.
  • Talasaz AH, Khalili H, Fahimi F, Jenab Y, Broumand MA, Salarifar M, Darabi F.Effects of N-acetylcysteine on the cardiac remodeling biomarkers and major adverse events following acute myocardial infarction: a randomized clinical trial. Am J Cardiovasc Drugs. 2014 Feb;14(1):51-61. doi: 10.1007/s40256-013-0048-x.
  • Khalili H, Talasaz AH, Salarifar M. Serum vitamin D concentration status and its correlation with early biomarkers of remodeling following acute myocardial infarction. Clin Res Cardiol. 2012 May;101(5):321-7. doi: 10.1007/s00392-011-0394-0.
  • Khalili H, Soudbakhsh A, Talasaz AH*. Severe hepatotoxicity and probable hepatorenal syndrome associated with sulfadiazine. Am J Health Syst Pharm. 2011 May 15;68(10):888-92.
  • Khalili H, Dashti-Khavidaki S, Talasaz AH, Tabeefar H, Hendoiee N. Descriptive analysis of a clinical pharmacy intervention to improve the appropriate use of stress ulcer prophylaxis in a hospital infectious disease ward. J Manag Care Pharm. 2010 Mar;16(2):114-21.
  • Talasaz AH, Abbasi MR, Abkhiz S, Dashti-Khavidaki S. Tribulus terrestris-induced severe nephrotoxicity in a young healthy male. Nephrol Dial Transplant. 2010 Nov;25(11):3792-3. doi: 10.1093/ndt/gfq457.

Honors/Awards

  • International Resident Travel Grant, ACCP
  • Travel Grant in Basic Sciences; European Society of Cardiology
  • International Cardiology Pharmacy Services (Travel Grant); ACCP
  • Cardiology Research and Scholarship Seed Grant Award, ACCP
  • Best Paper Award of the Year, ACCP Cardiology PRN
  • Eberhard F. Mammen STH Young Investigator Award
  • Young Investigator Award, ACCP Cardiology PRN

Professional Affiliations

  • Research Associate Professor Affiliate, Department of Pharmacotherapy and Outcome Sciences, VCU, Richmond, VA
  • Fellow, American College of Clinical Pharmacy
  • Fellow, American College of Cardiology